DDInter1846 DDInter542
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER-2 protein in tumours. It is suggested that the overexpression or gene amplification of HER2 has been found in about 20–30% of breast cancers and elevated activation of HER2 triggers multiple downstream pathways leading to abnormal proliferation of cancer cells. Trastuzumab binds to HER2 and suppresses cancer cell growth, proliferation, and survival directly and indirectly. In December 2017, FDA approved OGIVRI (
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Dicoumarol
Trastuzumab {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dicoumarol
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Niraparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Trastuzumab {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dicoumarol
Trastuzumab {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Trastuzumab {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Dicoumarol (Compound)
Trastuzumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dicoumarol (Compound)
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Trastuzumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dicoumarol (Compound)
Trastuzumab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Trastuzumab may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)